Top Medical News
Roshini Claire Anthony, an hour ago

Asian patients with ulcerative colitis have an elevated risk of colorectal cancer that persists decades after diagnosis, according to a systematic review and meta-analysis.

an hour ago
Topically administered rectal tacrolimus may effectively induce a clinical response, clinical remission and mucosal healing in resistant ulcerative proctitis, according to a study.
Jairia Dela Cruz, 5 hours ago
The use of the third-generation Sapien device in transcatheter aortic valve implantation (TAVI) affords favourable short-term outcomes, with high success rates, low procedural complications and excellent postimplant haemodynamics, according to the results of the SOURCE 3* study.
9 hours ago
Periconceptional consumption of alcohol presents an increased risk of small-for-gestational-age (SGA) births in a population of HIV-infected women initiating antiretroviral therapy (ART), a study has found.
Audrey Abella, 11 hours ago
Menarche at a younger age was associated with an increased risk of gestational diabetes mellitus (GDM), according to a recent cohort study.
Christina Lau, 12 hours ago

Reirradiation with intensity-modulated proton therapy (IMPT) shows promise in patients with recurrent thoracic tumours.

Rachel Soon, 12 hours ago

Providing more intravenous (IV) hydration during labour could reduce the frequency of caesarean operations, according to a new study.

Special Reports
Dr. Ross Soo, Prof. James Chih-Hsin Yang, Prof. Tony Mok, Prof. James Yang, 28 Mar 2017
Classification and treatment of non-small cell lung cancer (NSCLC) has greatly evolved in recent years. A better understanding of this complex malignancy has led to a shift from histologic diagnosis to more accurate subclassification using molecular screening which, in turn, led to the transition from empiric treatment to molecular target therapy. At the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore, Dr Ross Soo from the National University Cancer Institute, Singapore, Professor James Chih-Hsin Yang from the National Taiwan University Hospital, Taiwan, Professor Tony Mok from The Chinese University of Hong Kong, Hong Kong, and Professor Fred Hirsch from the University of Colorado Cancer Center, Colorado, US presented therapeutic biomarker-driven strategies for improving outcomes in patients with NSCLC. The discussion focused on the role and impact of molecular target therapy using epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) biomarkers and T-cell-based immunotherapy in coming up with algorithms to guide clinicians in selecting the best treatment regimen for each patient.
28 Mar 2017
Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. Probiotics have been used by humans to promote good health
since a century ago. They are also increasingly used in a variety of clinical conditions and this article summarizes some of these uses. 
20 Mar 2017
At the recent Asian Pacific Digestive Week (APDW) 2016 held in Kobe, Japan, three prominent international experts shared their views on gastroesophageal reflux disease (GERD) and the challenges of its management.
20 Mar 2017
At a recent lunch satellite symposium held in conjunction with the Malaysian Society of Anaesthesiologists & College of Anaesthesiologists Annual Scientific Congress 2016, Dr Choo Chee Yong talked about the current perspectives and clinical uses of oxycodone in managing postoperative pain.
17 Mar 2017
On 6 November 2016, in conjunction with the first year anniversary of vortioxetine (Brintellix®, Lundbeck) in Malaysia, two distinguished speakers, Professor Gin S Malhi and Dr Pranab Kalita shared updates on depression and the use of vortioxetine in order to help patients with major depressive disorders (MDD) to return to their premorbid functional states. The session was followed by three case presentations.
16 Mar 2017
Recently, Dr Peter Lin of the Canadian Heart Research Centre spoke on treatment strategies in the management of dyslipidaemia and T2DM at an AstraZeneca-sponsored continuing medical education event. Highlights of his presentations are summarized below.
13 Mar 2017
With the drive to share the current healthcare expert’s practices in managing different types of infections, Mundipharma conducted its 1st PLUS (Pharmacy cLinical UpdateS) Summit by inviting a group of consultants to share the role of povidone-iodine (PVP-I) in infection prevention and management with the community pharmacists on 15th–16th October 2016 in Port Dickson.
Conference Reports
Roshini Claire Anthony, 28 Mar 2017

The use of uninterrupted dabigatran before, during, and after catheter ablation in patients with atrial fibrillation (AF) resulted in fewer major bleeding complications than uninterrupted warfarin, according to results of the RE-CIRCUIT* trial.

Pearl Toh, 28 Mar 2017
Transcatheter aortic valve replacement (TAVR) is an effective and safe alternative to surgical aortic valve replacement (SAVR) for intermediate- and high-risk patients in the real world, with no significant difference in stroke and mortality rates at 1 year, and discharge to home being more common among TAVR patients, according to the ADVICE* study presented at the recent ACC.17 Scientific Session held in Washington, DC, US.
28 Mar 2017
Podcast: Dr Michael Reardon speaks on how the self-expanding TAVR is noninferior to SAVR in intermediate-risk AS patients in the SURTAVI trial.
28 Mar 2017
Podcast: Dr Marc Sabatine talks about the FOURIER Outcomes trial which shows lower CV events with the PCSK9 inhibitor evolocumab.
28 Mar 2017
Slideshow: Highlights from the American College of Cardiology 66th Annual Scientific Session (ACC)
Pearl Toh, 27 Mar 2017
Extended therapy with rivaroxaban was more effective than aspirin in reducing the risk of recurrent venous thromboembolism (VTE) with no significant increase in bleeding risk, according to data from the EINSTEIN CHOICE* study presented at the ACC.17 Scientific Session in Washington, DC, US.
Pearl Toh, 25 Mar 2017
Treatment with inclisiran, a siRNA for PCSK9 knockdown, delivers significant and sustained LDL-C lowering in a dose-dependent manner over 6 to 9 months in patients with high cardiovascular (CV) risk, according to the ORION-1* study presented at the ACC.17 Scientific Session held in Washington, DC, US.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!